Mylan's Purchase Of Matrix Will Speed Launch Of ANDAs
This article was originally published in The Pink Sheet Daily
Executive Summary
Acquisition of the Indian drug maker would give Mylan an edge on generic R&D and production costs as well as access to European markets.
You may also be interested in...
Mylan Wins Right To Acquire Merck KGaA Generics Business For $6.7 Billion
Global footprint will allow U.S. generics firm to maximize its follow-on biologics strategy, CEO Coury says.
Mylan Wins Right To Acquire Merck KGaA Generics Business For $6.7 Billion
Global footprint will allow U.S. generics firm to maximize its follow-on biologics strategy, CEO Coury says.
Indian Drug Companies Increasingly Active In Global M&A
Indian drug companies are actively making acquisitions and partnering deals in Europe and the U.S. in order to expand their geographic reach